KONVI
27.6.2024 09:01:30 CEST | Business Wire | Press release
Konvi, Europe’s leading luxury assets fractional investment platform, has announced the launch of a once-in-a-lifetime opportunity to invest in an exclusive Birkin bag designed by Alec Monopoly. This is a particularly exciting investment as it combines a piece of art by a prestigious artist with one of the best investment vehicles in the world – the Birkin bag – and the firm expects a high degree of interest from investors.
The value of a Birkin bag increases immediately upon leaving the store, leading many to say it’s a better investment than gold. Having never fluctuated downwards in value, Birkins are highly lucrative investments that consistently outperform the S&P 500 and boast double-digit annual returns.
Alec Monopoly rose to fame through his bright-coloured graffiti art and paintings which explore the themes of capitalism and luxury lifestyles. Birkin bags designed by Monopoly retail between an astounding $11,900 and $300,000. The famous handbags have also been sported by celebrities, including Khloe Kardashian, who owns a $25,000 piece painted by the artist.
Luxury assets are much more than a popular accessory, as they provide strong investment opportunities. The fact that returns on luxury items are negatively correlated with those on equities, bonds, and other collectible investments, makes them a great addition to an investment portfolio to ensure strong diversification.
Through Konvi’s app, investors can buy fractional shares of the luxury Birkin bag starting from €250 with immediate effect. Konvi buys and insures the asset and then sells it at the highest price, returning money to the asset's co-owners. This model enables users to access an extremely rare investment that would usually require significant capital and a broad network of collectors and auction houses to invest in.
Eran Peer, Co-Founder and CEO, commented: “Launching this exclusive luxury Alec Monopoly Birkin bag investment opportunity for Konvi users is central to our goal of bringing previously inaccessible luxury investment opportunities to a broader range of people. This offering means people can own a share in a bag adorned by some of the biggest celebrities on the planet, including the Kardashians, and reap the investment rewards. We’re excited to be bringing such a high-performing asset to our platform and look forward to launching similar investment opportunities in the near future.”
Investing in luxury assets such as art, fine wines, whiskeys, watches and vintage cars has long been inaccessible to the majority of people. High up-front costs, low availability and opaque, private markets with high fees mean historically only the most sophisticated investors and wealthy individuals could capitalise on these opportunities.
Konvi is the first Pan-European investment platform that enables retail investors to diversify their portfolios by fractionally investing in luxury assets. By collaborating with industry experts with strong track records, Konvi ensures that investment opportunities on its platform are carefully curated and accessible to everyone. Konvi also recently launched its latest Banksy art investment with one of the leading Banksy art piece curators, TGB Contemporary.
Visit Konvi’s website to find out how you can invest in this Alec Monopoly Birkin bag: https://konvi.app/en_GB/
About Konvi
Konvi is a pioneering online platform that democratises access to alternative investments, including hand-curated art, fine wine, classic cars, and more. With a user-friendly interface and innovative strategies, Konvi empowers individuals to build diversified portfolios and achieve their financial goals starting from an investment of €250.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627487145/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
